The market barely flinched at Stereotaxis today. The stock slipped about 1% to US$1.38, which is a muted move for a company trying to convince investors that this quarter marks something more important than just another loss on the income statement.

The real story is in the earnings mix. Stereotaxis reported Q2 2026 revenue of US$7.7m, with recurring revenue around US$6.2m and catheter sales sharply higher, while still posting a net loss of US$4.5m. The emotional gap is clear. The stock trades as if not much has changed, yet the quarter centered on whether recurring robotics revenue is finally taking the lead role in this story.

Love the idea of Stereotaxis building recurring robotics revenue but concerned that losses are still weighing on the story? Take a look at our list of solid balance sheet and fundamentals stocks (49 results) for companies that pair recurring revenue with sturdier financial footing.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$7.67m vs. US$8.80m (decline of about 12.9%)
• Net Income, Q2 2026 vs. Q2 2025: loss of US$4.78m vs. loss of US$4.14m (loss widened by about 15.4%)
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$0.0478 per share vs. loss of US$0.0471 per share (loss per share slightly higher, around 1.5%)
• Total Revenue, Trailing Twelve Months to Q2 2026 vs. Trailing Twelve Months to Q2 2025: US$30.07m vs. US$31.81m (decline of about 5.4%)

Prefer clear visual charts instead of another wall of earnings tables and footnotes? View Stereotaxis' full financial picture with an at-a-glance summary of its balance sheet strength in the interactive company report for Stereotaxis.

Stereotaxis Bull Case Hinges On Recurring Revenue Shift

Bulls argue Stereotaxis is turning its robotics platform into a recurring revenue engine built on proprietary catheters and software. Q2 gives concrete support to that claim. Recurring revenue reached about US$6.2m of US$7.7m total, and management highlighted very strong growth in robotically navigated catheter sales, with sequential growth around 270% and year on year growth described as very large. That aligns with the idea that MAGiC is beginning to replace third party disposables.

The recurring mix now sits alongside Synchrony, which already contributes early revenue and is in daily clinical use at several sites. System revenue was modest at US$1.5m, yet the first GenesisX purchase and a second planned installation indicate the hardware base is still expanding. For a thesis built on installed systems feeding higher margin recurring cash flows, these are important milestones, even while the income statement remains loss making.

Compare Stereotaxis's recurring revenue story with what the street is pricing in. See the consensus price target analysis for Stereotaxis to check whether analyst targets reflect this bullish earnings setup.

Stereotaxis Bear Fears On Profit Path Still Intact

Bears argue that Stereotaxis cannot fund its robotics and catheter expansion without prolonged losses and potential dilution. Q2 does not yet ease that concern. Revenue was US$7.7m with recurring revenue at US$6.2m, yet the company still reported an operating loss of US$4.6m and a net loss of US$4.5m. Free cash flow was negative US$3.7m and cash stood at US$10.5m with no debt. That combination keeps the spotlight on how long the current balance sheet can support the plan.

The bear view also questions whether recurring revenue can scale fast enough to offset high fixed costs. Catheter revenue grew very sharply and recurring margins of 66% help the story, but overall gross margin at 58% and continued losses show that the shift to a more recurring model is not yet translating into improving profitability.

After an operating loss of US$4.6m, a net loss of US$4.5m and less than one year of cash runway, review our risk analysis for Stereotaxis which shows 2 important warning signs

Own Your Next Investing Move

If Stereotaxis has your attention after this mix of rising recurring revenue and ongoing losses, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the story develops. When you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the key updates that matter to your holdings. For longer term context and fresh angles on Stereotaxis and similar stocks, tap into crowd insights through the Community. Spot potential catalysts and risks early so you can stay ahead of the market instead of reacting to it.

Seeking Alternatives Before The Crowd Moves

Fresh ideas do not stay under the radar for long. Spot potential breakout stories while the momentum is still building and before data goes stale. Act now.

• Kick start your hunt for resilient compounders by checking companies in the 90 resilient stocks with low risk scores. They may hold up better when sentiment turns and capital chases stability.
• Track where real earnings power meets AI momentum and review the curated 74 profitable AI stocks that aren't just burning cash before those cash generating stories get fully caught by the broader market.
• Get ahead of capital rotating into real assets by reviewing the focused 30 elite gold producer stocks while these producers stay under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.